CYBN / Can The Psychedelics Boom Go Bust? A Conversation With Cybin Chief Clinical Officer Dr. Alex Belser

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company co more_horizontal

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company co more_horizontal

Cybin Inc. (NYSE-A:CYBN, NEO:CYBN) shares maintained upward momentum on Wednesday after soaring earlier this week on the news New York Mets owner Stev more_horizontal

Shares of Cybin Inc., CYBN, +39.39% a developer of psychedelic therapies, finished 38.5% higher on Monday after billionaire investor and New York Mets more_horizontal

The global inflation surge and monetary policy tightening by major central banks have all contributed to the market volatility this year. Despite that more_horizontal

Cybin Inc. (NYSE-A:CYBN, NEO:CYBN) reported that it has narrowed its net loss year-over-year as it has advanced its two lead clinical programs CYB003 more_horizontal

Ever find yourself daydreaming about striking it rich in the stock market? Well, buckle up, because we're about to dive headfirst into the world of pe more_horizontal

Cybin Inc. (NYSE-A:CYBN, NEO:CYBN) shares moved higher just after the market opened on Wednesday after the psychedelics-focused biopharmaceutical c more_horizontal